“…The site of expression of HSD17B2 was identified in endothelial cells of fetal capillaries and some stem villous vessels (Moghrabi, et al, 1997;Takeyama, et al, 1998) and in endothelial cells of villous arteries and arterioles (Bonenfant, Blomquist, et al, 2000) in the close proximity of the fetal circulation. The reversible oxido-reductive interconversion of GABAergic C21 and C19 3Ǐ-hydroxy-5Ǐ/ǐ-reduced metabolites to the corresponding inactive 3-oxo-metabolites and antagonistic 3ǐ-hydroxy-metabolites (catalyzed by HSD17Bs an AKR1C1s) may also influence the balance between neuroinhibitory and neuroexcitatory steroids (Lundgren, et al, 2003). While the reductive conversion in the C3 position produce GABAergic steroids, the conversion of 20-oxo-to 20Ǐ-hydroxy-group or a modification of the C17,20 side chain in the 3Ǐ-hydroxy-5Ǐ/ǐ C21 steroids result in subtype dependent reduction of positive allosteric modulation of GABA A -r (Belelli, Lambert, Peters, Gee, & Lan, 1996).…”